Caitlyn Vlasschaert1, Amy J M McNaughton2, Michael Chong3,4,5,6, Elina K Cook2, Wilma Hopman7, Bryan Kestenbaum8, Cassianne Robinson-Cohen9, Jocelyn Garland7, Sarah M Moran7, Guillaume Paré3,4,5,6, Catherine M Clase10,11,12, Mila Tang13, Adeera Levin14, Rachel Holden7, Michael J Rauh2, Matthew B Lanktree3,10,11,12. 1. Department of Medicine, Queen's University, Kingston, Ontario, Canada caitlyn.vlasschaert@queensu.ca. 2. Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada. 3. Population Health Research Institute (PHRI), Hamilton, Ontario, Canada. 4. David Braley Cardiac, Vascular and Stroke Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada. 5. Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada. 6. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. 7. Department of Medicine, Queen's University, Kingston, Ontario, Canada. 8. Department of Medicine, University of Washington, Seattle, Washington. 9. Department of Medicine, Vanderbilt University, Nashville, Tennessee. 10. Department of Medicine, McMaster University, Hamilton, Ontario, Canada. 11. St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. 12. Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada. 13. St. Paul's Hospital, Vancouver, British Colombia, Canada. 14. Division of Nephrology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Abstract
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is an inflammatory premalignant disorder resulting from acquired genetic mutations in hematopoietic stem cells. This condition is common in aging populations and associated with cardiovascular morbidity and overall mortality, but its role in CKD is unknown. METHODS: We performed targeted sequencing to detect CHIP mutations in two independent cohorts of 87 and 85 adults with an eGFR<60 ml/min per 1.73m2. We also assessed kidney function, hematologic, and mineral bone disease parameters cross-sectionally at baseline, and collected creatinine measurements over the following 5-year period. RESULTS: At baseline, CHIP was detected in 18 of 87 (21%) and 25 of 85 (29%) cohort participants. Participants with CHIP were at higher risk of kidney failure, as predicted by the Kidney Failure Risk Equation (KFRE), compared with those without CHIP. Individuals with CHIP manifested a 2.2-fold increased risk of a 50% decline in eGFR or ESKD over 5 years of follow-up (hazard ratio 2.2; 95% confidence interval, 1.2 to 3.8) in a Cox proportional hazard model adjusted for age, sex, and baseline eGFR. The addition of CHIP to 2-year and 5-year calibrated KFRE risk models improved ESKD predictions. Those with CHIP also had lower hemoglobin, higher ferritin, and higher red blood cell mean corpuscular volume versus those without CHIP. CONCLUSIONS: In this exploratory analysis of individuals with preexisting CKD, CHIP was associated with higher baseline KFRE scores, greater progression of CKD, and anemia. Further research is needed to define the nature of the relationship between CHIP and kidney disease progression.
BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP) is an inflammatory premalignant disorder resulting from acquired genetic mutations in hematopoietic stem cells. This condition is common in aging populations and associated with cardiovascular morbidity and overall mortality, but its role in CKD is unknown. METHODS: We performed targeted sequencing to detect CHIP mutations in two independent cohorts of 87 and 85 adults with an eGFR<60 ml/min per 1.73m2. We also assessed kidney function, hematologic, and mineral bone disease parameters cross-sectionally at baseline, and collected creatinine measurements over the following 5-year period. RESULTS: At baseline, CHIP was detected in 18 of 87 (21%) and 25 of 85 (29%) cohort participants. Participants with CHIP were at higher risk of kidney failure, as predicted by the Kidney Failure Risk Equation (KFRE), compared with those without CHIP. Individuals with CHIP manifested a 2.2-fold increased risk of a 50% decline in eGFR or ESKD over 5 years of follow-up (hazard ratio 2.2; 95% confidence interval, 1.2 to 3.8) in a Cox proportional hazard model adjusted for age, sex, and baseline eGFR. The addition of CHIP to 2-year and 5-year calibrated KFRE risk models improved ESKD predictions. Those with CHIP also had lower hemoglobin, higher ferritin, and higher red blood cell mean corpuscular volume versus those without CHIP. CONCLUSIONS: In this exploratory analysis of individuals with preexisting CKD, CHIP was associated with higher baseline KFRE scores, greater progression of CKD, and anemia. Further research is needed to define the nature of the relationship between CHIP and kidney disease progression.
Authors: Catherine C Coombs; Ahmet Zehir; Sean M Devlin; Ashwin Kishtagari; Aijazuddin Syed; Philip Jonsson; David M Hyman; David B Solit; Mark E Robson; José Baselga; Maria E Arcila; Marc Ladanyi; Martin S Tallman; Ross L Levine; Michael F Berger Journal: Cell Stem Cell Date: 2017-08-10 Impact factor: 24.633
Authors: Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Giulio Genovese; Anna K Kähler; Robert E Handsaker; Johan Lindberg; Samuel A Rose; Samuel F Bakhoum; Kimberly Chambert; Eran Mick; Benjamin M Neale; Menachem Fromer; Shaun M Purcell; Oscar Svantesson; Mikael Landén; Martin Höglund; Sören Lehmann; Stacey B Gabriel; Jennifer L Moran; Eric S Lander; Patrick F Sullivan; Pamela Sklar; Henrik Grönberg; Christina M Hultman; Steven A McCarroll Journal: N Engl J Med Date: 2014-11-26 Impact factor: 91.245
Authors: Jocelyn S Garland; Rachel M Holden; Wilma M Hopman; Sudeep S Gill; Robert L Nolan; A Ross Morton Journal: J Ren Nutr Date: 2012-04-28 Impact factor: 3.655
Authors: Jocelyn S Garland; Rachel M Holden; Patti A Groome; Miu Lam; Robert L Nolan; A Ross Morton; William Pickett Journal: Am J Kidney Dis Date: 2008-06-17 Impact factor: 8.860
Authors: Jasmine D Kerr; Rachel M Holden; Alexander R Morton; Robert L Nolan; Wilma M Hopman; Cynthia M Pruss; Jocelyn S Garland Journal: BMC Nephrol Date: 2013-01-26 Impact factor: 2.388
Authors: Miriam Díez-Díez; Marta Amorós-Pérez; Jorge de la Barrera; Enrique Vázquez; Ana Quintas; Domingo A Pascual-Figal; Ana Dopazo; Fátima Sánchez-Cabo; Monica E Kleinman; Leslie B Gordon; Valentín Fuster; Vicente Andrés; José J Fuster Journal: Geroscience Date: 2022-06-25 Impact factor: 7.713